A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life.

Menopause · 2023 · PMC10155698 · PMID 36809193

Europe PMC DOI

hedged sentences

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

almost reached significanceP = 0.069so close (0.05 < p ≤ 0.1)

It was maximal with E4 15 mg with a significant difference versus placebo at W4 ( P = 0.011) that almost reached significance at W12 ( P = 0.069).

also in 62 other papers

highly significantno p-value reported

The observed changes in the E4 15 mg group from baseline to W12 were highly significant for all domain items except for bladder problems (Table 5 ).

also in 29,987 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.